Tests tocilizumab given before or only during CAR-T side effects in blood cancers
Compares early tocilizumab with symptom-triggered use in adults with blood cancers.
Plain-language title generated from the registry record
Registry title: PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Key facts
- Where
- Bern, SwitzerlandSee the site
- Phase
- Phase 2
Where in Switzerland
- Insel Gruppe AGBern, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT06430736
- Record updated
- 8 July 2024
- Original description
Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients.Read full original descriptionShow less
Prospective Comparison Between Prophylactic and On-demand Use of Tocilizumab in CAR-T Recipients - a Randomized, Two Arm, Open-label, Single-center Trial
Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients.
This study aims to identify safety and efficacy of prophylactic Tocilizumab treatment. In particular, to explore whether prophylactic Tocilizumab treatment can decrease the incidence and severity of CRS (and subsequent eventual neurotoxicity) following CAR-T-treatment.
Inclusion: Patients planned to receive commercial CAR-T treatment for all registered indications comprising lymphomas, leukemias or myeloma at a single academic center (Bern Inselspital); With written informed consent; Considered by the investigator to be clinically fit for this treatment; Patients aged ≥18 years.
Exclusion: Previous Tocilizumab treatment within 3 months prior to CAR-T infusion; Patients with treatment with an investigational compound within 8 weeks prior to CAR-T infusion; Previous enrolment into the current study; Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant; Women who are pregnant or breast feeding, or women intending to become pregnant during the study period; or participants lacking safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases during study treatment and for a total of 12 months; Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential; Enrolment of the investigator, his/her family members, employees and other dependent persons.